Experienced Team.
Focused Innovation.

Based in Galway, Ireland and Atlanta, USA, Versono Medical is supported by £19 million in private innovation funding and backed by a leadership team with deep expertise in endovascular technology development.

Experienced Senior Management Team

FinbarD

Finbar Dolan

PhD MBA CEng
CEO & Board Member
HughOD

Hugh O'Donoghue

BEng
CTO & Board Member
PadraicC

Padraic Clarke

CFO, Board Member and Chair of Remuneration
Finbar-Dolan 1

Mark Harty

CCO
Finbar-Dolan 1 (1)

Lea Doyle

Head of Clinical &
Regulatory Affairs

Exceptional Experienced Respected
linical Advisory Board

CraigW

Dr Craig Walker

MD
ChrisLS

Dr Chris LeSar

MD
EricD

Dr Eric Dippel

MD
JihadAM

Dr Jihad A. Mustapha​

MD
ThomasZ

Dr Thomas Zeller

MD
Finbar-Dolan 1 (2)

Dr Derek Mittlieder

MD
Finbar-Dolan 1 (3)

Dr Fadi Saab

MD

Respected Non-Executive Independent Board

JimG

Jim Greene

Chairman
JohnOS

John O'Shaughnesey

Non-Executive Director, Strategy & Management
MarkG

Mark Gibbs

Versmed Nominees
NigelJ

Nigel Jones

Non-Executive Director, Chair, Audit & Risk Committee
MairsilC

Mairsíl Claffey

Non-Executive Director, Clinical Regulatory
PeterW

Peter Walsh

Non-Executive Director, Stategic Partners

Investment Partners

Our core investors are comprised of clinicians and medical device domain professionals as well as the following institutional investment organisations:

Business Venture Partners (BVP)

Enterprise Ireland

Western Development Commission

VerseMed Nominees

Co-Funded by the European Union

 Join Us in Advancing Endovascular Innovation

Follow our journey
CONTACT US
FinbarD

Finbar Dolan

PhD MBA CEng

CEO & Board Member

Finbar is responsible for leading, developing VERSONO’s short and long-term strategy and the overall management of the company’s operations. His role also involves developing and communicating VERSONO’s vision and mission with its stakeholders, customers, board of directors and government agencies. Finbar has over 20 years of executive and leadership experience within the Medical Device Industry and has worked with CR Bard, Medtronic, GTI, Lake Region/Integer, Arc Devices, in product development, strategic R&D and manufacturing operations.

Finbar has also contributed on a pro bono basis to initiatives in IBEC’s MedTech Ireland, the IRDG, the American Chamber of Commerce Ireland and Engineers Ireland. A chartered engineer, Finbar holds PhD, MBA and BSc degrees and is a BioInnovate fellow.

HughOD

Hugh O'Donoghue

BEng

CTO & Board Member

Hugh is the co-founder and CTO of Versono Medical, and has responsibility for outlining the company’s technological vision, implementing its strategies, and ensuring that resources are aligned to delivery on the company’s business goals and objectives.  Hugh holds a B.Sc. in Engineering with over 25 years’ experience, including 20 years in the medical device industry with Bausch and Lomb, American Visionwear (US start-up), CRBard and most recently Medtronic.  Throughout his career he has taken up challenging positions to further his knowledge and broaden his understanding across a number of different business functions, and has held leadership positions in Medtronic within Engineering, Regulatory Affairs, and Operations, and has extensive experience in managing and supporting coronary and peripheral devices in each stage of the product lifecycle from development to commercialization.

More recently, Hugh has provided Operations leadership to a number of key strategic projects including Joint Venture/Localisation programs, Product Development Programs, Partner Due Diligence assessments, and significant technology transfer programs transferring entire manufacturing operations to and from Ireland. Hugh has a thorough understanding and practical experience of the Quality and Operations Systems required within the med-tech industry, which is supported by his strong technical background and understanding of the sector and the broader device industry.

PadraicC

Padraic Clarke

CFO, Board Member and Chair of Remuneration

After serving for a number of years supporting the company as a Non-Executive Board Member Padraic assumed the role of CFO in 2022 and with it the planning, implementation, and managing the financial activities of the company, including business planning, budgeting, forecasting and negotiations.  Padraic’s previous experiences incorporated many senior roles, including CFO with Creganna Tactx Medical, and CEO of Socrates Healthcare where he led the company through a fund-raise, the strategic development of new products and the ultimate sale of the business. More recently, he was CFO of Atlantic Therapeutics, a company that develops unique solutions for the treatment of incontinence. There together with the Atlantic Therapeutics CEO, he led the spin out of the business from Biomedical Research and the raising of over €47m in debt and equity to support the development, launch & commercialization of the company’s product, INNOVO in Europe and the US.

Finbar-Dolan 1

Mark Harty

CCO

Mark Harty is a senior MedTech commercial leader with extensive international experience in bringing vascular and endovascular technologies from development through to market adoption with major Global MedTech organisations.  
His career spans strategic commercialisation, market development, distributor network expansion, and cross-functional leadership within high-growth medical device environments. Mark has worked closely with clinical stakeholders, executive teams, and investors to translate technical innovation into structured commercial pathways.
At Versono, Mark leads commercial strategy and market preparation, ensuring that clinical development is aligned with real-world procedural needs and adoption dynamics. His focus is on disciplined execution, scalable infrastructure, and responsible market entry planning.
Mark brings a pragmatic, operator-led perspective to growth, grounded in deep knowledge of vascular markets and the realities of introducing new technology into complex healthcare systems.
 
Finbar-Dolan 1 (1)

Lea Doyle

Head of Clinical & Regulatory Affairs

TBA

CraigW

Dr Craig Walker

MD

Clinical Professor of Medicine, Tulane Medical School Cardiovascular Institute of the South, Tulane Medical School, Houma, Louisiana.

Dr Craig Walker is board certified in internal medicine, cardiovascular disease, and interventional cardiology. He is a fellow of the American College of Cardiology, the American College of Physicians, the American Society of Cardiovascular Interventionists, the International College of Angiology, the Society for Cardiac Angiography and Interventions, the American College of Chest Physicians and the Council on Clinical Cardiology.

He is the clinical editor of Vascular Disease Management and Global Vascular Digesta and sites on the editorial board of 13 journals. Dr Walker is the author and co-author of more than 300 published articles and more than 30 book chapters. Dr Walker is a Clinical Professor of Medicine at Tulane School of Medicine and LSU School of Medicine in New Orleans, Louisiana.

Dr Walker established the Cardiovascular Institute of the South in 1983 with more than 55 physicians and 700 employees throughout Louisiana,

Mississippi, and Texas. In January 2021, Dr Walker opened CIS’s first Ambulatory Surgery Centre in Gray.

Dr Craig Walker received his medical degree from the LSU School of Medicine in New Orleans. He completed a cardiology fellowship at Ochsner Foundation Hospital in New Orleans and subsequently a research fellowship at Harvard Medical School and Brigham Women’s Hospital in Boston, Massachusetts.

ChrisLS

Dr Chris LeSar

MD

Chris LeSar is a vascular-endovascular surgeon, with a professional interest in utilising new, advanced, minimally invasive techniques for the treatment of cerebral vascular, mesenteric, renal, venous, and peripheral vascular diseases. He has a special interest in caring for patients with critical limb ischaemia, with the ultimate goal of preventing unnecessary amputations.

EricD

Dr Eric Dippel

MD

Dr. Eric Dippel, MD is a Cardiologist in Davenport, IA. Dr. Dippel completed their Medical School at University Of Iowa College Of Medicine. Following their education, Dr. Dippel was board certified by the American Board of Interventional Cardiology.

JihadAM

Dr Jihad A. Mustapha​

MD

Co-founder and CEO ACV Centres Michigan State University College of Human Medicine, Grand Rapids, Michigan

Dr Mustapha is a board-certified interventional cardiologist who specializes in endovascular revascularization of critical limb ischemia. He is co-founder and CEO of Advanced Cardiac & Vascular Centres for Amputation Prevention in Grand Rapids, Michigan,

Dr Mustapha is a Fellow of the American College of Cardiology and Fellow of the Society of Cardiac Angiography and Intervention. He serves as Clinical Associate Professor of Medicine at Michigan State University College of Osteopathic Medicine. Dr Mustapha speaks internationally on the topic of CLI, alternative access, atherectomy, vessel morphology, calcification, and drug eluting technology. He has multiple publications on CLI and limb salvage. Dr Mustapha is the Founder and Director of the Amputation Prevention Symposium and is a Founding Board Member of the CLI Global Society.

He graduated from Wayne State University and St. George University School of Medicine and has completed Fellowships in both Cardiology and Interventional Cardiology at Louisiana State University School of Medicine

ThomasZ

Dr Thomas Zeller

MD

Director Department Angiology at the Universitaets – Herzzentrum Freiburg, Bad Krozingen, Germany.

Dr Thomas Zeller performs interventional angiology with more than 20 years of experience in this field. His main research interest is diagnostic and therapy of renal artery stenosis, optimization of endovascular therapy methods of peripheral arterial occlusive disease and optimization of non-invasive diagnostic methods in vascular medicine. He has performed a series of studies in these areas and has conducted numerous clinical trials.

Furthermore, he is editorial board member of various scientific journals, e.g. VASA, EURO Intervention, Vascular Medicine, Catheterization Cardiovascular Interventions, Journal of Endovascular Therapy, gefaessmedizin.net. He is the author of more than 200 peer reviewed original and review articles, editor of the textbook Vascular Medicine – Therapy and Practice as well as reviewer for European Heart Journal, Journal of American College of Cardiology and sub-journals, Circulation and sub-journals, The Lancet and others.

Finbar-Dolan 1 (2)

Dr Derek Mittlieder

MD

TBA

Finbar-Dolan 1 (3)

Dr Fadi Saab

MD

TBA

JimG

Jim Greene

Chairman

TBA

JohnOS

John O'Shaughnesey

Non-Executive Director, Strategy & Management

John’s current role within Versono Medical Ltd has the responsibility for focusing on strategic matters, overseeing Versono’s business and setting high governance standards. John is not a novice within the medical device industry having over 30 years’ experience and would be ranked as one of the leading entrepreneurs in his field. Having founded and not only successfully taken many businesses from concept to a strategic exit but also introduced many new life-changing therapies to markets world-wide. Some of John’s innovative companies where MedNova Ltd, the company was sold to Abbott Laboratories, Cambus Medical and Vistamed, both companies were sold to Freudenburg Medical and most recently the spectacularly successful Neuravi Ltd who was sold to multinational giant Johnson & Johnson.

John is an advocate and founding member of Croi, (the West of Ireland Cardiac Foundation), a voluntary organization to support the fight against heart disease and stroke.

MarkG

Mark Gibbs

Versmed Nominees

Mark is a Partner and Director of Corporate Finance in DHKN, .

Mark specialises in Mergers & Acquisitions, MBOs, raising finance, company valuations, business disposals and other corporate finance related activities.

Recent transactions include:

Completed sale mandates for a range of SME businesses with recent transaction values ranging from €15m – €45m;

Completed over €180m funding for companies through equity issues, debt solutions and the Employment & Investment Incentive Scheme (EIIS);

Engaged by an Irish plc on an ongoing basis to identify potential acquisition targets, provide valuation and diligence services;

Mark has over 25 years’ experience and prior to joining DHKN, he worked in senior roles with PwC, Independent News and Media Plc and Microsoft;

Mark is a fellow of the Institute of Chartered Accountants (FCA) and has an MBA from the Smurfit School of Business.

NigelJ

Nigel Jones

Non-Executive Director, Chair, Audit & Risk Committee

Nigel helps the company turn risks into opportunities, including in the legal and intellectual property areas, and in relation to the wellbeing of our people. He builds on his 32 year career in the City of London (partner at law firm Linklaters), his other Board and Advisory Board experience in the commercial and charitable sectors, and his work as an executive coach and wellbeing consultant.  He has extensive experience in advising leading organisations in the healthcare, pharmaceutical, medtech and biotech sectors on intellectual property, regulatory and commercial matters. This includes co-ordinating international patent disputes; working with companies and investment banks on M&A and finance transactions; and identifying and implementing innovative ways for such organisations to make the most of their intellectual property rights. He has also worked with many organisations to help them understand the importance of wellbeing to business success, and develop and implement ways of achieving that critical business goal.

MairsilC

Mairsíl Claffey

Non-Executive Director, Clinical Regulatory

Mairsíl Claffey has a career spanning over 25 years in the medical industry and is expert in Quality, Clinical, and Regulatory. She holds a degree in Polymer Engineering and a post grad.dip. In Clinical Research from NUIG.

In MedNova Ltd, and subsequently Neuravi Ltd. she built the quality, regulatory and clinical teams and led successful product strategies from drawing board, through clinicals, and regulatory, to full PMA and 510k product clearance respectively.

As well as successfully building startup functions, she has an impressive history of success in corporate roles including as Director of Carotid Regulatory, Global for Abbott Vascular, and Vice President, Quality and Regulatory International, with Teleflex Inc.  In both these leadership roles her scope of activity included the execution of due diligence for potential acquisitions and, in case of purchase, the subsequent transfer and assimilation of regulatory licenses and departments.

On the Board of Versono Medical Ltd. Mairsíl will provide strategic oversight on the path of Versono’s products through design and development, quality system implementation, regulatory decision making, and clinical study planning, to full product approval in Europe and the United States.

PeterW

Peter Walsh

Non-Executive Director, Stategic Partners

Peter’s current role as a Board Member and Advisor with Versono Medical Ltd is instrumental in helping the company develop and execute its go to market strategies. With over 30 years’ experience within the medical device industry, Peter brings rich experience to Versono including sourcing, manufacturing strategies and systems, leadership and talent development. Over his 17 years with Medtronic Peter led operations at a site, business unit, group and corporate level. His roles included responsibility for global sourcing, manufacturing and distribution, which included over 90 manufacturing sites, 40,000 employees and a large supplier and distribution network.